Affordable Access

deepdyve-link
Publisher Website

Current status and prospects for development of a vaccine against Trichomonas vaginalis infections.

Authors
  • Smith, Jeffrey1
  • Garber, Gary E2
  • 1 University of Ottawa, Faculty of Medicine, Ottawa, ON, Canada. , (Canada)
  • 2 University of Ottawa, Faculty of Medicine, Ottawa, ON, Canada; Ottawa Hospital Research Institute, Division of Infectious Disease and Public Health Ontario, Ottawa, ON, Canada. Electronic address: [email protected] , (Canada)
Type
Published Article
Journal
Vaccine
Publication Date
Mar 20, 2014
Volume
32
Issue
14
Pages
1588–1594
Identifiers
DOI: 10.1016/j.vaccine.2013.07.050
PMID: 23916988
Source
Medline
Keywords
License
Unknown

Abstract

Trichomonas vaginalis is a sexually transmitted pathogen with an annual worldwide incidence of over 276 million infections, the highest of all curable and non-viral STI. A large proportion of cases are asymptomatic and under-diagnosed with conventional diagnostic tools. Infection has important maternal and fetal health consequences and can lead to a higher probability of HIV transmission and susceptibility. Lack of affordable accurate diagnostic tests globally and metronidazole resistance hinder T. vaginalis control efforts. Based on data from current vaccination studies in animal models, a human vaccine is achievable to intervene on the substantial incidence of infection.

Report this publication

Statistics

Seen <100 times